The placenta shares identical growth mechanisms, antigenic determinants, and immune evasion characteristics with cancer cells. Subsequent decades of research have uncovered further similarities between placenta and tumors in developmental biology, cell biology, proteomics, and epigenetics. Building upon these discoveries, a series of tumor immunotherapies based on placental cells and proteins have been developed, such as heat shock protein (HSP) and IPS/ESC tumor prevention and treatment vaccine therapies. This product significantly stimulates the generation of tumor antigen-specific T cells in vitro, enabling more precise targeting and elimination of tumor cells. It is suitable for research into the prevention and treatment of various solid tumors.